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Genotypinga b s t r a c t
We present an electronic format for exchanging data for HLA and KIR genotyping with extensions
for next-generation sequencing (NGS). This format addresses NGS data exchange by refining the
Histoimmunogenetics Markup Language (HML) to conform to the proposed Minimum Information for
Reporting Immunogenomic NGS Genotyping (MIRING) reporting guidelines (miring.immunogenomics.
org). Our refinements of HML include two major additions. First, NGS is supported by new XML structures
to capture additional NGS data and metadata required to produce a genotyping result, including analysis-
dependent (dynamic) and method-dependent (static) components. A full genotype, consensus sequence,
and the surrounding metadata are included directly, while the raw sequence reads and platform docu-
mentation are externally referenced. Second, genotype ambiguity is fully represented by integrating
Genotype List Strings, which use a hierarchical set of delimiters to represent allele and genotype
ambiguity in a complete and accurate fashion. HML also continues to enable the transmission of legacy
methods (e.g. site-specific oligonucleotide, sequence-specific priming, and Sequence Based Typing (SBT)),
adding features such as allowing multiple group-specific sequencing primers, and fully leveraging
techniques that combine multiple methods to obtain a single result, such as SBT integrated with NGS.
 2015 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and
Immunogenetics. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. Introduction ibility. Methods for generating this information have dramaticallyHuman leukocyte antigen (HLA) genotyping is fundamental for
research and clinical practice in immunogenetics and histocompat-improved in the last three decades, from pioneering serological
methods to modern DNA-based genotyping methods [1], revealing
over time a seemingly never ending expansion of allele diversity
[2], and presenting the subsequent challenge of reinterpretation
of earlier results in light of new knowledge [3–6]. It has become
increasingly clear that in order to ‘future-proof’ the results as much
as possible, data standards are needed for recording and reporting
of these results which include not only the allele assignments, but
also the metadata (data describing other data) surrounding
laboratory methods and allele assignment rules [5,7].
A new generation of sequencing methods has compounded this
challenge. These methods are characterized by massively parallel
technologies leading to high throughput sequencing, allowing for
routine interrogation of not only select regions of a gene, but also
whole-exon or whole-gene sequencing. While these technologies,
commonly known as next-generation sequencing (NGS), have
existed for several years, their application to HLA has been
964 R.P. Milius et al. / Human Immunology 76 (2015) 963–974challenging due to a high degree of allelic polymorphism, the lack
of robust genomic reference alignments for the MHC region, and
the complex metadata required for allele assignment and later
reinterpretation as reference sequences are refined and expanded.
These considerations emphasize the need for recording and
reporting complete metadata surrounding data collection, and in
particular for data processing and interpretation.
Recently, a group of histocompatibility and immunogenetics
stakeholders including clinicians, researchers, instrument manu-
facturers and software developers has gathered in a series of meet-
ings to develop standards for recording and reporting NGS based
genotyping of HLA [8]. One of the goals of these meetings has been
to identify the Minimum Information for Reporting Immunoge-
nomic NGS Genotyping (MIRING) [9] based on the principles of
the reporting guidelines for the Minimum Information for
Biological and Biomedical Investigations (MIBBI) [10]. The MIRING
identifies eight principles for reporting NGS based genotyping of
immunogenomics data. While the MIRING provides principles
and guidelines, it does not provide a technical specification.
To develop a technical specification that meets these principles,
we have extended the Histoimmunogenetic Markup Language
(HML) [11]. HML is an electronic messaging format based on
XML and developed as a community standard allowing explicit
representation of genotyping results for polymorphic immuno-
genetic gene systems such as HLA and KIR. Primary data in the
form of Sequence Specific Oligonucleotide (SSO)/Sequence Specific
Primer (SSP) reactivities and Sequence Based Typing (SBT)
sequences can be linked with nomenclature-based allele assign-
ment. The primary purpose of HML is reporting genotyping results.
Because of its use of structured data, it can inform those sending
and receiving this data on their requirements for its storage and
management. In extending HML, we added the ability to include
reporting of NGS based genotyping, including metadata surround-
ing the primary data and acquisition methods, consensus
sequences, variant calling including novel polymorphisms, and
reporting full allele and genotype ambiguity through the use of
Genotype List (GL) Strings [12].Typing Method Allele Assignment
Consensus 
Sequence
Header
Fig. 1. HML overall structure.2. Methods
The development of HML 1.0 was led by the National Marrow
Donor Program (NMDP) through a series of meetings and discus-
sions with the HLA Information Exchange Data Format Standards
Group, and later with the Immunogenomic NGS Data Consortium
[8], a community of registries, clinical and research laboratories,
and industry partners focused on identifying and addressing
specific data-reporting requirements for NGS-based genotyping,
and occurred in parallel with development of MIRING.
In September 2014, a community of stakeholders including
researchers, clinicians, software developers, sequencing platform
vendors, HLA and KIR sequence database developers and adminis-
trators, registry and donor center IT professionals, and laboratory
support staff gathered to attend a Data Standards Hackathon
(DaSH) [13] to develop new ways to exchange NGS data for HLA
and KIR. During this event the current state of HML was vetted
by the community, and at the same time MIRING was further
refined. These exercises led to new substantial requirements for
the final specification for HML 1.0, which contains all the function-
ality of earlier versions, such as HML 0.3.3, but with the added
capabilities of allowing the addition of information required by
MIRING principles.
A rapid prototyping approach was used for the development of
XML schemas for HML. An agile approach where as schemas were
developed, example messages were created with various scenarios
of HLA and KIR genotyping and syntactically validated usingautomated validation tools. The schema and examples can be found
at https://bioinformatics.bethematchclinical.org/HLA-Resources/
HML/.
In designing HML, it was important to accommodate the use of
pointers to external references and datasets. This allows users to
reuse previously registered metadata, and to reference datasets
that are impractical to include in the HML message. These include
registered methodologies, reference sequences, and raw sequence
reads. The use of pointers to external sources is a practical neces-
sity considering the large size of much of this data. Those charged
with maintaining these resources must be clear on the service level
users can expect, as well as expectations for their continued
availability.3. Results
HML 1.0 retains similar overall structure to previous versions,
but with notable changes. As with earlier versions, reporting of pri-
mary data is separated from allele assignment. NGS is supported by
new XML structures to capture all NGS data and metadata required
to produce a genotyping result, including analysis-dependent
(dynamic) and method-dependent (static) components. Pointers
to external locations refer to registered methods, raw NGS reads,
and reference standards. A separate component describing consen-
sus sequences and variants was created specifically to accommo-
date NGS data, but could be used for other methodologies if
desired. This component includes metadata describing the consen-
sus sequences such as references sequences, phasing information,
expected copy number, sequence block continuity, and other meta-
data. Reporting of allele assignment with full genotypic and allelic
ambiguity is achieved through the use of GL Strings.
The overall HML 1.0 structure is seen in Fig. 1. An HML message
has four main sections: the document header, the typing methods,
the allele assignment, and the consensus sequence. An HML mes-
sage will contain the document metadata, and data describing
one or more samples, generated with one or more typing methods
for one or more gene families.
In addition to several minor improvements and many other
components left to retain backward compatibility, two major
improvements were introduced in HML 1.0. First, new elements
that conform to the MIRING reporting guidelines were added. Sec-
ond, GL strings were added to allow expression of full allelic and
genotypic ambiguity in addition to, and eventually in lieu of, NMDP
allele codes. Although the expectation is that NGS will lead to
unambiguous allele assignment through full gene sequencing, ear-
lier methodologies will continue to be used and reported in HML
1.0, and in the near term NGS based genotyping may be limited
by some laboratories to interrogating specific exons leading to
allele and genotype ambiguity. Additional changes include
enhancements to Sanger-Sequence Based Typing (SBT-Sanger),
external references to typing kit information, and expansions to
include multiple gene families (e.g., HLA, KIR).
In the specification below, note that the declared element and
attribute names are in Courier font to highlight their abstract
nature.
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The header details are seen in Fig. 2. Here, the message is
contextualized, providing details such as identifying the lab send-
ing the message, the report identifier, the sample(s) the report
describes, and other reference information. This header does not
contain details about any particular test, only the context in which
it occurred.
3.1.1. hmlid
A unique identifier for the HML document can be included
through the hmlid element. The hmlid follows the HL7
convention for instance identifiers using a two-part key [14]. An
ISO Object Identifier (OID) [15] may be provided through the root
attribute and often represents the unique organization identifier
publicly registered for an organization. The extension attribute
contains the unique document id managed internally by the
reporting organization. Together, the root and extension
attributes combine to provide a globally unique identifier.
Alternatively the ISO OID may be extended directly with the
extension in the root, or a Universally Unique Identifier (UUID),
also known as Globally Unique Identifier (GUID), may be provided
in the root without an extension. Examples of these different
ways of using hmlid are found in Fig. 3.hml
version *
project-na
collection-method
hmlid reporting-center
root *
extension
reporting-center-id *
reporting-center-context
i
c
g
d
Typing Method Al
[ 0..1 ] [ 0..1 ]
[ 0..* ]
[ 1 ]
Fig. 2. He
OID using separate root and extension 
<hmlid extension="123456789" root
OID using only root
<hmlid root="2.16.840.1.113883.3.
UUID/GUID
<hmlid root="1ee83ff1-08ab-4fe7-b
Fig. 3. Examples of how3.1.2. reporting-center
The reporting-center element identifies the entity/organi-
zation sending the HML message. If included, it must contain a
unique reporting-center-id identifying the sender. A new
attribute, reporting-center-context, has been added. This is
used to report the context/naming authority of the identifier.
This can be used by different organizations to identify the
reporting organization using registered contact information. For
example, although this element is optional, NMDP requires
the reporting-center element in an operational context. If
the reporting-center-context is not included, it is assumed to be
‘‘NMDP” and is a unique identifier that is registered with the
NMDP. Another example of the use of this element is to refer to
a testing lab registered in the NCBI Genetic Testing Registry
(GTR) [16] through the GTR Lab ID. Fig. 4 shows examples of
how reporting-center-id may be used.
3.1.3. typing-test-names
The typing-test-names element specifies a list of test
names internally referenced by the SSO or SSP typing methods.
It contains a test-id attribute associated with one or more
typing-test-name containing test identifiers, which together
are used to define a typing kit. It wraps a list of typing-test-
name elements containing the test identifiers. The test-id isme
sample typing-test-names
test-id *d *enter-code
typing
ene-family *
ate *
typing-test-name
name *
lele Assignment Consensus Sequence
[ 1..* ]
[ 0..* ][ 1..* ]
[ 1..* ]
[ 0..* ] [ 0..* ]
element
required attribute *
optional attribute
ader.
="2.16.840.1.113883.3.1470"/>
1470.123456789"/>
573-ea777e9bad51"/>
hmlid can be used.
<reporting-center 
<reporting-center 
Lab ID registered with the NCBI Genetic Testing Registry
<reporting-center 
   reporting-center-id="000000" 
   reporting-center-context="NCBI GTR"/>
Fig. 4. Examples of how reporting-center can be used.
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and SSP typing methods sections.
3.1.4. sample
An HML message contains one or more sample elements
enclosing the genotyping data pertaining to a particular sample.
The id and center-code attributes identify the sample and the
organization where the sample originated (e.g., transplant or donor
center) respectively. Multiple samples from the same individual, or
different individuals can be included in a single HML message. A
collection-method element may be used to identify how the
sample was collected, e.g., swab, filter paper, blood aliquot. Each
sample may be associated with multiple typing elements.
3.1.4.1. typing. The typing element encapsulates the primary data
from a genotyping method with a genotyping result (allele-as-
signment) that was determined from the primary data (typing-
method) and/or consensus sequences (consensus-sequence).[ 0..1 ] [ 0..1 ]
[ 1 ] [ 0..* ]
[ 0..1
typin
sbt-sangersso ssp
locus 
test-id 
test-id-source 
scores *
registered-name *
locus 
test-id 
test-id-source 
scores *
locus 
test-id 
test-id-source 
sequence sequence
registered-name *
Fig. 5. Typing methodsThe gene-family attribute is used to constrain the typing to gene
family name recognized by the HUGOGene Nomenclature Commit-
tee [17] (e.g., HLA, KIR).3.2. Genotyping method and primary data
Fig. 5 describes typing method and primary data elements. Here
the method used to perform the genotyping and the primary
un-interpreted results from that method are reported. This can
be one of SSO, SSP, SBT-Sanger, or SBT-NGS.3.2.1. Test IDs and locus
To comply with MIRING requirements, three new attributes ref-
erencing additional metadata are available to more fully describe
the method and locus targeted for each typing method. Two of
these attributes name a test registrar (test-id-source) and an
identifier (test-id) that can be dereferenced through the regis-
trar. In previous versions of HML, sso and ssp elements referenced
test information in the test-id element found in the header,
which is used for encapsulating the test methods consisting of
one or more individual tests or probe kits within the HML docu-
ment. These new attributes allow labs to register their test method
in an external testing registrars, such as the NCBI GTR [16].
The third new attribute for each typing method element is
locus, which indicates the target of the typing method. locus is
an optional attribute. If present this must be a gene name
recognized by the HUGO Gene Nomenclature Committee [17],
e.g., HLA-A, HLA-DRB1, KIR2DL1.3.2.2. sso and ssp
The sso and ssp elements describe SSO and SSP genotyping
methods, respectively. These elements are unchanged from
previous versions of HML except for the addition of test-id,
test-id-source, and locus attributes (see above). For[ 0..* ]
[ 0..* ]
 ]
[ 0..* ]
g-method
gssp
element
required attribute *
optional attribute
registered-name
primer-sequence
primer-target
sbt-ngs
sequence
locus 
test-id 
test-id-source 
raw-reads
uri *
format *
paired *
pooled *
availability
adapter-trimmed
quality-trimmed
and primary data.
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typing-test-name structure found in the header is expected.
3.2.3. sbt-sanger
The sbt (Sequence-Based Typing) element found in previous
versions of HML has been renamed to sbt-sanger. This reflects
the recognition that both Sanger and NGS typing methods are
sequence based, but with differences in the metadata needed to
support them. Other changes include an additional child element
to support sub-amplification primers and results. These primers
are used to resolve ambiguities and may be used either concur-
rently with or after the amplification step. In addition, multiple
GSSP elements (Group Specific Sequencing Primers), describing
PCR primer sequences used to amplify polymorphic regions of
sequences, are now allowed. In previous versions of HML, only a
single GSSP was allowed.
3.2.4. sbt-ngs
The new sbt-ngs element describes Sequence Based Typing
using high throughput methods, also known as NGS (next-
generation sequencing). As with other methods, test-id,
test-id-source, and locus attributes describe the method
and the target locus of the test. Each sbt-ngs may contain multi-
ple raw-reads child elements.
The raw-reads element references the raw sequence reads
generated by an NGS platform. This data can be quite large even[ 0..* ]
allele-assig
date *
allele-db
allele-versio
haploid genotyp
diploid-com
locus-block
locus *
method *
type *
diploid-com
allele-list
allele
present
strin
Fig. 6. Allele asfor relatively small regions of the genome. Because of this, if the
raw-reads are provided, this information is not directly embed-
ded in the HML document, but instead is referenced through a
uri (Uniform Resource Identifier) attribute that points to an exter-
nal location and a format attribute that describes how the data is
stored (e.g., the NCBI Sequence Read Archive (SRA)). Other attri-
butes include the availability of the raw reads (public, private,
or with permission) and processing metadata indicating whether
or not the data are pooled (pooled), if the adapters have been
trimmed (adapter-trimmed), or whether low-quality sequences
have been trimmed (quality-trimmed).
3.3. Allele assignment
Fig. 6 describes the allele assignment section. Several changes
from previous versions of HML were made here. The element that
was previously named interpretation is now renamed
allele-assignment to more accurately reflect its purpose. Also,
this element includes new attributes that describe the allele
database or other source of the nomenclature (allele-db, e.g.,
IMGT-HLA Database) and release version of the database
(allele-version, e.g., 3.19.0) that was used for the allele
assignment.
Allele assignment may be reported in three different formats. As
in previous versions of HML, haploid and genotype-list
elements are available and unchanged. A new third element[ 0..* ]
[ 1..* ]
[ 1..* ]
[ 1..* ]
[ 1..* ]
[ 1..2 ]
nment
n
glstringe-list
uri
bination
[ 0..* ]
element
required attribute *
optional attribute
bination
string
g
signment.
Fig. 7. Example of how allele-assignment may be used with glstring.
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allele assignments with full genotype and allele ambiguity [12],
has been added. The GL String may be directly included, or a URI
resource identifier pointing to a service that provides the GL String
(e.g., https://gl.nmdp.org) may be used. An example of how a GL
String may be reported is seen in Fig. 7.
3.4. Consensus sequence
Fig. 8 describes the consensus sequence section. This is a new
structure in HML that was created to provide the result of an[ 1..* ]
[ 1..*]
[ 1 ]
consensu
date *
reference-database
sequence
reference-sequence
conse
name
description
version
availability *
curated
uri
iupac-bases
referen
start
end
strand
phase-
continu
expect
descrip
id *
name
description
start
end
accession
strand
uri
Fig. 8. Consensualignment or assembly of shorter sequence reads generated by a
NGS platform. It is dependent on a number of dynamic factors such
as the processing pipeline including software and inputs, and refer-
ences sequences used for alignments. This is not considered to be
primary data, but rather as a type of interpretation. For this reason,
it is not included within the typing method section, but is consid-
ered separately. While this section was created with NGS in mind,
it may be used by other sequence-based typing methods if desired.
This section is largely based onmany of the data elements found
in the Variant Call Format (VCF) [18] and metadata identified from
the MIRING [9]. Note HML uses start and end attributes with a
0-based coordinate system with closed-open ranges, i.e., the range
includes the start position, but excludes the end position. This
convention is used in many genomic data models (e.g., Global Alli-
ance for Genomics and Health schemas [19,20], UCSC browser [21],
BED files) because of its programming benefits. In contrast, the VCF
specification indexes the 1st base having position 1.
A sequence is reported directly through the sequence element.
A pointer to an external reference may also be included, or as vari-
ant of a reference sequence. If a variant is reported, the structure
provides a method to report variant effects. Position specific qual-
ity values may also be recorded.[ 0..* ]
[ 0..* ]
[ 0..* ]
s-sequence
element
required attribute *
optional attribute
nsus-sequence-block
ce-sequence-id *
set
ity
ed-copy-number
tion
variant
id
name
start *
end *
reference-bases *
alternate-bases *
quality-score
uri
variant-effect
term *
hgvs
uri
sequence-quality
sequence-start *
sequence-end *
quality-score *
[ 0..* ]
s sequence.
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Together, the reference-database and reference-
sequence elements describe the database containing the refer-
ence sequence used within the consensus-sequence-blocks.
The reference-database may point to whole genome builds
(e.g., Genome Reference Consortium), allele databases (e.g.,
IMGT-HLA Database), or another database containing sequences
that are used as a reference (e.g., GenBank, EMBL-ENA). Metadata
surrounding the reference-database include the name, a
description, the version, its availability, whether or not the data-
base is curated, and a URI pointing to its external location. In the
case where de novo assembly is being used rather than alignment
to a reference, availability is set to none.
For each reference-database, one or more reference-
sequence elements may be described. An id is used to uniquely
identify the reference-sequence and is referenced by the
consensus-sequence-block. Other metadata that may be
provided as attributes include the name of the sequence, the start
and end positions, an accession id, and a URI pointing the sequence
directly.
Examples of how reference-database and reference-
sequence can be used are found in Fig. 9.Fig. 9. Examples of using reference-d3.4.2. consensus-sequence-block
A consensus-sequence-block encapsulates a DNA sequence
consisting of IUPAC nucleotides [22] and variants against a refer-
ence sequence if an exact match is not found, and associated meta-
data. A reference-sequence-id is required and points to a
reference-sequence found within the HML document. Start
and end positions identify a targeted region on the reference. Other
optional metadata are provided through attributes that describe
the strand being identified, a description of the target region (e.
g., ‘‘HLA-A exon 3”), a phase set identifier to associate different
consensus-sequence-blocks, a continuity flag to indicate
whether a gap exists between blocks, and an expected-copy-
number to indicated how many copies of the sequence block was
expected.
A quality score for positions within the consensus sequence
may be captured in the sequence-quality element, using
sequence-start and sequence-end attributes indicating the
region of interest. Quality metrics for sequence quality vary by
platform reflecting differences in sequencing chemistry and digital
processing. Additional metrics, such as coverage depth at the
sequence- and variant-levels (see below), lack common standards
and may be calculated differently depending on the analyticalatabase and reference-sequence.
970 R.P. Milius et al. / Human Immunology 76 (2015) 963–974method chosen. For these reasons HML quality reporting does not
impose strict specification criteria.3.4.3. variant and variant-effect
A variant element must be included if the sequence does not
completelymatch the reference-sequence. A typical use for this
element is describing a novel allele. The available attributes for
variant corresponds with many data elements used in VCF files
[18] and in theMIRING. The id attribute is used to uniquely identify
the variant within the HML document. The start and end identify
the coordinates of the reference sequence where the variant occurs.
The nucleotides found at this region of the reference and what they
are replace with are identified with the reference-bases and
alternate-bases attributes, respectively.
An alternative external reference for the variant may be
reported using the uri attribute. This could be a location for a
VCF file, or an alternative format that represents the same
information.
A child of variant, the variant-effect element reports the
effect of this variation. The effect or effects should be described
using Sequence Ontology (SO) variant effect terms [23] (e.g., mis-
sense_variant, stop_gained, downstream_gene_variant). Additional
attributes may be used to provide more information on the effect,Fig. 10. Example of consensus-see.g., severity, POLYPHEN prediction, SIFT score [24,25]. In addition
to the term, a Human Genome Variation Society (HGVS) nomen-
clature string [26,27] may be included. A uri may be used to
provide an external reference for this variant effect.
This use of variant and variant-effect elements naturally
applies to reference guided assemblies. In the case of de novo
assembly where no reference is used, associating a variant effect
is difficult in this schema unless the reference database and refer-
ence alleles are used explicitly for this purpose.
An example of how variants may be captured is seen in Fig. 10.3.5. Extensibility
HML provides for extensibility using two methods. One is
through the use of the property element that has been intro-
duced as an optional child element for several nodes (hml, sample,
typing, typing-method types, and allele-assignment). Here,
name/value pairs (jointly defined and agreed upon by the creator
and consumer of the HML document) may be entered. Additionally,
property elements may contain custom nested structures of the
creator’s choosing to add additional information and details to
the enclosing element. The other method of extending the HML
specification is through the use of the anyAttribute typequence-block with variants.
Table 1
Mapping of MIRING elements to HML solutions.
MIRING elements HML solution example with comment
1 Message Annotation
1.1 Unique MIRING Message Identifier <hmlid root=‘‘x.x.x.x” extension=‘‘x” />
root may be ISO Object Identifier (OID) or Universally Unique Identifier (UUID)
1.2 Message Generator Contact
Information
Using an NCBI GTR Lab ID:
<reporting-center
reporting-center-id=‘‘000000”
reporting-center-context=”NCBI-GTR” />
1.3 Platform Documentation Using an NCBI GTR Test ID:
<sbt-ngs . . .
test-id=”GTR000000000.0”
test-id-source=”NCBI-GTR” />
1.4 Read Processing Documentation
Reference
Using an NCBI GTR Test ID:
<sbt-ngs . . .
test-id=”GTR000000000.0”
test-id-source=”NCBI-GTR” />
1.5 Primary Data Availability <raw-reads . . . availability=”true” . . . />
1.6 Primary Data Reference <raw-reads . . .
uri=”http://www.ncbi.nlm.nih.gov/sra/SRX000000” . . . />
2 Reference Context
2.1 Reference Sequence Database Version
for Allele Calling
For allele assignment, the allele database and version is captured in attributes:
<allele-assignment . . .
allele-db=”IMGT-HLADB”
allele-version=”3.19.0” >
<glstring>. . .</glstring>
</allele-assignment>
For sequence variant, the reference database and sequence is identified through the reference-database and reference-
sequence elements.
<reference-database >
<reference-sequence . . . />
<reference-database. . . />
</reference-database>
2.2 Individual Reference Sequences
Applied
<reference-sequence
id=”0”
name=”HSCHR6_MHC_MCF_CTG1”
start=”0”
end=”4827813”
accession=”CCDS34373.12”
uri=”http://www.ncbi.nlm.nih.gov/nuccore/GL000254.2”/>
2.2.1 Reference Sequence Identifier <reference-sequence . . . id=”0” . . . />
2.3 Reference Sequence Source Type <reference-database . . .
public=”true”
curated=”true”
. . . />
3 Full Genotype
3.1 Pertinent Locus/Loci GL Strings should be reported with the locus captured in the gene name
<glstring>
HLA-DPB1⁄02:01:02 + HLA-DPB1⁄03:01:01
</glstring>
Locus is also captured as an attribute in the typing method
<sbt-ngs . . . locus=”HLA-DPB1” . . . />
3.2 Formatted Genotype <glstring>
HLA-DPB1⁄02:01:02+HLA-DPB1⁄03:01:01
</glstring>
3.3 Genotype Uniform Resource Identifier
(URI)
<glstring
uri=”https://gl.nmdp.org/imgt-hla/3.19.0/genotype-list/2”/>
4 Consensus Sequence
4.1 Consensus Sequence Block (CSB) <consensus-sequence-block . . . />
<sequence>. . .</sequence>
<variant . . . >
<variant-effect>
</consensus-sequence-block>
4.2 Consensus Sequence Descriptor Note: the pipe-delimited descriptor found in MIRING is required for FASTA files. Often this same information is found
within the XML structure of HML and may not be explicitly needed
(continued on next page)
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Table 1 (continued)
MIRING elements HML solution example with comment
4.2.1 Consensus Sequence Block Identifier In HML, the consensus-sequence-blocks are captured sequentially, and each block contains within it all pertinent
information within the attributes and child elements. Because of this, a separate identifier for the consensus sequence
block is not needed
<consensus-sequence>
<consensus-sequence-block . . . >
. . . </consensus-sequence-block>
<consensus-sequence-block . . . >
. . . </consensus-sequence-block>
</consensus-sequence>
4.2.2 Reference Sequence Identifier <reference-sequence id=”0” . . . > . . . </reference-sequence>
4.2.3 Reference Sequence Coordinate <reference-sequence start=”0” end=”4827813” . . . />
4.2.4 Phase Set <consensus-sequence-block phase-set=”0” . . . > . . .
</consensus-sequence-block>
4.2.5 Copy Number <consensus-sequence-block expected-copy-number=”1” . . . > . . .
</consensus-sequence-block>
4.2.6 Reference Sequence Match A match of the consensus-sequence-block to the reference is indicated by the presence or absence of a variant child
Reference sequence match = true
<consensus-sequence-block . . . >
<sequence > . . . </sequence>
</consensus-sequence-block>
Reference sequence match = false
<consensus-sequence-block . . . >
<sequence > . . . </sequence>
<variant . . . > . . . </variant>
</consensus-sequence-block>
4.2.7 Sequence Continuity <consensus-sequence-block . . . continuity=”true” . . . >
5 Novel Polymorphisms
5.1 Reference For allele assignment, the allele database and version is captured in attributes
<allele-assignment . . .
allele-db=”IMGT-HLADB”
allele-version=”3.19.0” >
<glstring> . . .</glstring>
</allele-assignment>
For sequence variant, the reference sequence is identified through the reference-database and reference-sequence
elements.
<reference-database >
<reference-sequence . . . />
<reference-sequence . . . />
</reference-database>
5.2 Position <variant start=”123” end=”124” . . . />
5.3 Variant Identifier <variant id=”0” . . . />
5.4 Reference Sequence <variant reference-bases=”A” . . . />
5.5 Variant Sequence <variant alternate-bases=”TCG” . . . />
5.6 Quality Score <variant quality=”90” />
5.7 Quality Filter Status <variant filter=”pass”
5.8 INSDC Accession Number <reference-sequence . . . accession=”GL000254.2” . . . />
While the accession number for the reference sequence can be provided in HML, there is no provision for providing one
for the variant sequence. If an accession number is available, then for the purposes of the report, it is considered a
reference and matched. Since this is optional (‘‘when possible”) in the MIRING, we do not see this as an issue. If a
separate accession number for the variant is needed, consensus-sequence-block may be extended through the
anyAttribute attribute, but this must be agreed upon by the creator and consumer of the HML message
6 Platform Documentation Using an NCBI GTR Test ID:
<sbt-ngs . . .
test-id=”GTR000000000.0”
test-id-source=”NCBI-GTR” />
7 Read Processing Documentation NCBI GTR should be used for describing overall methods and pipeline strategy, i.e., standard methods and SOPs for
running the test
<sbt-ngs . . .
test-id=”GTR000000000.0”
test-id-source=”NCBI-GTR” />
Dynamic methodology that can change with each sequencing run should be captured with an Sequence Read Archive
like data structure that is reported through the raw-reads uri attribute. This is also where run specific software
parameters may be recorded
<raw-reads . . .
uri=”http://www.ncbi.nlm.nih.gov/sra/SRX000000” . . . />
8 Primary Data <raw-reads . . .
uri=”http://www.ncbi.nlm.nih.gov/sra/SRX000000” . . . />
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variant, and variant-effect elements that allows additional
attributes not specified by the schema.4. Discussion
We present HML 1.0, an electronic format for exchanging data
for genotyping of histoimmunogenetic markers such as HLA and
KIR, with extensions for next-generation sequencing. These
improvements equip the message with the mechanisms to collect
new forms of typing data and accurately report genotype and allele
ambiguity, in a machine-readable format that tightly pairs the typ-
ing method and result for downstream analyses.
4.1. MIRING
We have extended and enhanced HML to implement the princi-
ples and guidelines outlined by the MIRING. Eight elements were
identified that need to be addressed in an MIRING compliant geno-
typing report.
MIRING elements and corresponding example solutions in HML
1.0 are presented in Table 1. In several cases, the MIRING offers
technical solutions for how specific elements may be addressed,
but these translate into different solutions in HML. For example,
the pipe-delimited descriptor found in MIRING is required for
FASTA files. Often this same information is found within the XML
structure of HML and may not be explicitly needed. For example,
in HML the consensus-sequence-blocks are captured sequen-
tially, and each block contains within it all pertinent information
within the attributes and child elements. Because of this, a sepa-
rate identifier for the consensus sequence block to associate
sequences with consensus sequences, references sequences, vari-
ants and associated metadata is not needed.
4.2. Validation
HML 1.0 has been finalized and the XML schema and examples
can be found on https://bioinformatics.bethematchclinical.org/
HLA-Resources/HML/. Reporting of NGS based genotyping of HLA
and KIR conforming to MIRING principles is possible using a com-
bination of HML and semantic and syntactic validation tools, cur-
rently under development. A syntactically correct HML
genotyping report may not pass organization specific business
rules for acceptance or compliance to reporting guidelines such
as MIRING. On the other hand, business-specific HML messages
should conform to, and validate with, public XML schema defini-
tions (XSDs). Transparent validation encourages a standards-
based approach to mutual exchange of data for reproducible
research and clinical application. Because of this, different valida-
tion tools will need to be developed depending on use cases and
degree of semantic validation. For example, when a URI is
presented to refer to external data and metadata, the validator will
need to assess whether the link exists, and whether the
information it points to makes sense and is interpretable. If HML
is extended through the use of property elements and
anyAttribute attributes, validation is further complicated since
they are largely ignored with syntactic validation tools. Robust
validation tools for these special use cases must then be created.
A tool to validate whether a given instance of a HML message is
MIRING compliant is being developed.
4.3. Future work
HML 1.0 has been developed to serve the needs of the
immunogenomics community. However we recognize the needfor interoperability with the larger healthcare community and
the potential to interface with EMR systems. In light of this, the
possibility to encapsulate HML in HL7 messages or clinical struc-
tured documents is being explored.
HML is a standard derived from the community members listed
above. However, the NMDP has a commitment to using standards
developed andmaintained by other parties whenever possible. HL7
is an international standards development organization committed
to the interchange of healthcare data. We are investigating the util-
ity of OIDs (referred to above) as unique identifiers, as well as HL7
interchange formats such as Clinical Document Architecture (CDA)
and Fast Healthcare Interoperability Resources (FHIR) to encapsu-
late HML. There is an active community to develop these standards
that serves a larger audience than the parties listed in this docu-
ment. We are actively engaged with the HL7 Clinical Genomics
Working Group to ensure the content contained in the HML 1.0
specification can be contained in an HL7 message. This will allow
the parties listed here to leverage the standards developed and
implemented by the HL7 community. HL7 is also a party to the
Biomedical Research Integrated Domain Group (BRIDG) as a con-
sortium member including the FDA, CDISC, and NCI. The BRIDG
members are developing artifacts to assist in the interchange of
study-driven protocols and their regulatory artifacts, but also to
assist in the interchange of molecular testing as part of the LSDAM
(Life Sciences Domain Analysis Model). Since the HML 1.0 model is,
at its core, an encapsulation of the results of a molecular test, we
wish to leverage the work of those parties as well.
To support HML 1.0, utility tools for validation and support in
an NGS pipeline are being developed (e.g., https://github.com/
nmdp-bioinformatics/ngs). This includes command line validation
of HML as well as other NGS pipeline tools. Documentation for this
development effort surround HML can be found at http://
nmdp-bioinformatics.github.io/ngs/apidocs/org/nmdp/ngs/hml/
package-summary.html.
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